Recce Pharma says commercial potential of its anti-infectives is gaining recognition

–News Direct–

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive soon after announcing the company has raised a total of around $11 million across its recent placement, entitlement offer and shortfall as it develops a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The capital raised will fund various clinical trials, build out Recces infectious diseases portfolio, geographical expansion, and serve as general working capital.

Graham said, We are extremely pleased to complete such a successful fundraising and thank investors for their support. This puts the company in an excellent position to progress its Phase 1/2 trials and to expand its multiple clinical stage infectious diseases portfolio.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

[email protected]

View source version on

Recce Pharmaceuticals Ltd

comtex tracking